Skip to main content


Presenter: Bernard Combe, Montpellier University, France.

Wednesday 12 June: 16:15–17:45 (Abstract LB0001)

FINCH 1 is a phase III randomized trial in which 1759 participants with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate were randomly assigned to receive the Janus kinase I inhibitor filgotinib, placebo, or the active comparator adalimumab, all given in combination with methotrexate. The primary outcome is the proportion of patients with an ACR20 response at week 12.

More on this trial